English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Received June 6, 2016 Accepted October 20, 2016 We report the case of a patient with oxaliplatin-induced thrombocytopenia during chemotherapy for colorectal cancer. In this patient, the administration of oxaliplatin was discontinued due to an allergic reaction during the 16 course of chemotherapy with oxaliplatin. The 17 or subsequent courses of chemotherapy were performed without changing the regimen, leading to drug-induced thrombocytopenia. Although oxaliplatin-induced thrombocytopenia has been reported as an adverse reaction, its incidence is low, and other factors causing thrombocytopenia are present, making diagnosis difficult. In the case of thrombocytopenia complicated with an allergic reaction to oxaliplatin, we consider the immunological mechanism, and measurement of platelet associated immunoglobulinG can be performed, too. When chemotherapy-related allergic symptoms are mild, administration is continued in many cases, considering the advantages of the treatment. However, the possibility that readministration may induce serious adverse reactions must be considered.

Case Report of a Patient with Drug-Induced Thrombocytopenia Related to Readministration after Discontinuation due to Allergy to Oxaliplatin